Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Gastric and gastroesophageal junction cancer (G/GEJC) is a heterogeneous and complex disease characterized by histologic and molecular subtypes. Although a growing number of treatments have improved survival outcomes in the advanced setting, the greatest therapeutic benefits are observed among patient populations eligible for biomarker-directed therapies. Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) is an emerging biomarker under phase 3 clinical investigation for G/GEJC with the novel monoclonal antibody bemarituzumab. FGFR2b protein overexpression in gastric cancer, together with its function in various oncogenic signaling pathways, makes it an attractive target for precision medicine and thereby has gained clinical interest for its potential prognostic role in G/GEJC. Thus, to explore the potential role of FGFR2b, this narrative review summarizes the role and mechanism of FGFR2b in advanced G/GEJC, describes appropriate detection methodology for FGFR2b protein overexpression, and discusses future considerations for precision treatment in advanced G/GEJC with respect to FGFR2b protein overexpression and the emergence of other biomarkers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctrv.2025.102971 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent FGFR2 and PIK3CA Mutations in Sialoblastoma.
Head Neck Pathol
September 2025
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Purpose: Sialoblastoma is an extremely rare low-grade malignant salivary gland neoplasm that presents at birth or early infancy and has heterogeneous clinical behavior. Due to its rarity, the molecular landscape remains incompletely characterized. We aimed to expand the current understanding of the genetic alterations in sialoblastoma through comprehensive molecular analysis.
View Article and Find Full Text PDFSynergistic Anticancer Effects of Fibroblast Growth Factor Receptor Inhibitor and Cannabidiol in Colorectal Cancer.
Nutrients
August 2025
Division of Colon and Rectal Surgery, Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea.
Background/objectives: Colorectal cancer (CRC) remains a significant global health concern, with limited treatment options for metastatic stage 4 CRC. Fibroblast Growth Factor Receptor (FGFR) is a promising therapeutic target in CRC, while cannabidiol (CBD) has shown potential for inducing cell death and overcoming drug resistance. This study evaluates the efficacy of FGFR inhibitors and explores the synergistic effects of combining FGFR inhibitors with CBD in inducing apoptosis in CRC cells.
View Article and Find Full Text PDFMaturation Status of Rat Lung Epithelial Cells in Interspecies Chimeras Generated by Blastocyst Complementation.
Genes Cells
September 2025
Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan.
This study investigates the maturation status of rat lung epithelial cells in interspecies chimeras generated via blastocyst complementation (BC) using Fgfr2b-knockout mouse embryos. In our previous study, we succeeded in generating rat-derived lung epithelium in interspecies chimeras using tetraploid complementation; however, the resulting cells remained immature and failed to support respiratory function. In this study, we established two Fgfr2b-KO mouse lines via CRISPR/Cas9 and injected GFP-labeled rat embryonic stem (ES) cells into blastocysts, which were then transferred to pseudopregnant female mice.
View Article and Find Full Text PDFTargeting FGFR2 with natural products: Discovery and experimental validation of torosanin as a potent and selective therapeutic candidate for gallbladder cancer.
Int J Biol Macromol
September 2025
Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, Hubei, China. Electronic address:
Gallbladder cancer (GBC) is a highly aggressive malignancy of the biliary tract with limited treatment options and poor prognosis. Fibroblast Growth Factor Receptor 2 (FGFR2) alterations play a crucial role in GBC progression, driving oncogenic signaling pathways and tumor aggressiveness, making it a promising therapeutic target. This study aims to identify potent natural product-derived inhibitors of FGFR2 by screening African natural product databases (EANPDB, NANPDB, SANCDB) using virtual drug screening, molecular dynamics simulation and binding free energy calculation.
View Article and Find Full Text PDFIdentification of miRNA/FGFR2 Axis in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Int J Mol Sci
July 2025
Laboratory of Molecular Medicine, National Institute of Gastroenterology IRCCS "S. de Bellis", Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with different clinical and biological characteristics. Ki-67 staining and mitotic counts are the most commonly used prognostic markers, but these methods are time-consuming and lack reproducibility, highlighting the need for innovative approaches that improve histological evaluation and prognosis. In our previous study, we observed that the microRNA (miRNA) expression profile of GEP-NENs correlates with the three grades of GEP-NENs.
View Article and Find Full Text PDF